The Expression of CD8+ and MHC-I in Cervical Cancer with HPV Infection

Adi Prayitno, Elyana Asnar, Okid Parama Astirin, Suhartono Taat Putra

Mathematical and Science Faculty of Sebelas Maret University, Surakarta, Indonesia.
Medical School of Airlangga University, Surabaya, Indonesia.
Medical School of Sebelas Maret University, Surakarta, Indonesia.

DOI: 10.4236/jct.2013.45A003                

Abstract

Introduction: The immunity against cervical cancers is many unknown. Major histocompatability complex class I (MHC-I) with the alpha domain has binding site for Cytotoxic T cells (CD8+) to target cells. The objective of this experiment is to know the expression of CD8+ and MHC-I in cervical cancer with HPV infection. Method: DNA was isolated from seventeen sample cervical cancer tissues frozen section. Diagnose related with HPV was made by PCR. Paraffin block of the tissues was cut in thoroughly cleaned cryotome and place in glass plate that covered with poly-elysine. The immuno-histochemistry is done with monoclonal antibody again MHC-I and CD8+ with TSA-indirect method. The power of expression was counted the number of positive cells to express the MHC-I and CD8+ every 100 cells per one view look. Result: The Result of this experiment shows that expression of MHC-I and CD8+ in cervical cancer with HPV infection is in mild category (30% - 70%). Conclusion: Immunity against uterine cancer played by MHC-I and CD8+ is in milt category. The experiment that related with uterine cancer immunology is suggested.

Keywords

CD8+; MHC-I; HPV; Cervical Cancer

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	G. Schmits, “Overview: Epidemiology and Diagnosis of Cervical Cancer,” Proceeding Seminar Nasional Upaya Peningkatan Deteksi HPV Pada Kanker Serviks Secara Biologi Molekuler Dan Pengelolaannya. Pusat Kedokteran Tropis, Gajah Mada University, Yogyakarta, 1997, pp. 1-42.
[2]	A. Prayitno, “Cervical Cancer with Human Papilloma virus and Epstein Barr virus Positif,” Journal of Carcinogenesis, Vol. 5, No. 13, 2006, pp. 1-4. doi:10.1186/1477-3163-5-13
[3]	L. Pusztai, C. E. Lewis and E. Yap, “Cell Proliferation in Cancer—Regulation Mechanisms of Neoplastic Cell Growth,” Oxford University Press, Oxford, New York, Tokyo, 1996.
[4]	R. S. Cotrans, V. Kumar and S. L. Robbins, “Robbins Patologic Basis of Disease,” 6th Edition, WB Saunders Co., London, 1997, pp. 604-607.
[5]	D. Male, “Immunologi: An Illustrated Online,” 2nd Edition, Mosby, St. Louis, Toronto, 1994.
[6]	A. Venuti, “Progress and Challenges in the VaccineBased Treatment of Head and Neck Cancers,” Journal of Experimental & Clinical Cancer Research, Vol. 28, No. 69, 2009. doi:10.1186/1756-9966-28-69
[7]	O. J. Finn, “Cancer Immunology,” New England Journal of Medicine, Vol. 358, 008, pp. 2704-2715.
[8]	C. L. Berger, N. Wang, I. Christensen, J. Longley, P. Heald and R. L. Edelson, “The Immune Response to Class I-Associated Tumor-Specific Cutaneous T-Cell Lymphoma Antigens,” Journal of Investigative Dermatology, Vol. 107, 1996, pp. 392-397. doi:10.1111/1523-1747.ep12363378
[9]	H. L. Smits, “Species Diagnostics Protocols: PCR and Other Nucleic Acid Methods,” In: J. P. C. Humana, Ed., Methods in Molecular Biology, Press Inc., Totowa, 1994.
[10]	M. Nigel and F. Nina, “Typing of HPV Isolates by PCR: Molecular Approach Toward Vaccine Development for Viral Infection. Icro-Unesco Training Course, At Inter University Center for Biotecnology,” Gajah Mada University, Yogyakarta, 1998.
[11]	J. H. L. Playfair, “Immunology at a Glance,” 5th Edition, Blackwell Scientific Publications, London, 1993.
[12]	I. Roitts, J. Brostoff and D. Male, “Immunology,” 3rd Edition, Mosby, St. Louis, Toronto, 1993.
[13]	F. S. Rosen, L. Steiner and E. R. Unanue, “Macmillan Dictionary of Immunology,” Macmillan Reference Books, 1989.
[14]	D. P. Stites and A. I. Terr, “Basic Human Immunology,” 1st Edition, Prentice-Hall International Inc., Connecticut, 1991, pp. 34-44.
[15]	S. Cornain, “Immune Response against Viral Infection: Molecular Approach toward Vaccine Development for Viral Infection. Icro-Unesco Training Course, At Inter University Center for Biotecnology,” Gajah Mada University, Yogyakarta, 1998.
[16]	R. S. Cotrans, V. Kumar and S. L. Robbins, “Robbins Patologic Basis of Disease,” 6th Edition, WB Saunders Co., London, 1999, pp. 604-607.
[17]	J. J. Stein, “Virology, Immunology, and Immunotherapy of Malignant Disease,” Cancer, Vol. 34, No. 4, 1974, pp. 1343-1346.
[18]	R. M. Welsh, L. K. Selin and E. Szomolanyi-Tsuda, “Immunological Memory to Viral Infections,” Annual Review of Immunology, Vol. 22, 2004, pp. 711-743. doi:10.1146/annurev.immunol.22.012 703.104527
[19]	S. Koyama, T. Ebihara and K. Fukao, “Expression of Intercellular Adhesion Molecule 1 (ICAM-1) during the Development of Invasion and/or Metastasis of Gastric Carcinoma,” Journal of Cancer Research and Clinical Oncology, Vol. 118, No. 8, 1992, pp. 609-614. doi:10.1007/BF01211806
[20]	K. G. Karnen, “Imunologi Dasar,” Penerbit Fakultas Kedokteran Universitas Indonesia, Jakarta, 1988, pp. 49-57.
[21]	C. L. Berger, N. Wang, I. Christensen, J. Longley, P. Heald and R. L. Edelson, “The Immune Response to Class I-Associated Tumor-Specific Cutaneous T-Cell Lymphoma Antigens,” Journal of Investigative Dermatology, Vol. 107, 1996, pp. 392-397. doi:10.1111/1523-1747.ep12363378
[22]	I. Galea, J. Stasakova, M. S. Dunscombe, C. H. Ottensmeier, T. Elliott and S. M. Thirdborough, “CD8+ T-Cell Cross-Competition Is Governed by Peptide-MHC Class I Stability,” European Journal of Immunology, Vol. 42, No. 1, 2012, pp. 256-263.
[23]	M Naoe, Y Marumoto, R Ishizaki, Y Ogawa, Y Nakagami and H. Yoshida, “Correlation between Major His tocompatibility Complex Class I Molecules and CD8+ T Lymphocytes in Prostate, and Quantification of CD8 and Interferon-Gamma mRNA in Prostate Tissue Specimens,” BJU International, Vol. 90, No. 7, 2002, pp. 748-753.
[24]	E. S. Jordanova, A. Gorter, Ou. Ayachi, F. Prins, L. G. Durrant, G. G. Kenter, S. H. van der Burg and G. J. Fleuren, “Human Leukocyte Antigen Class I, MHC Class I Chain-Related Molecule A, and CD8+/Regulatory T-Cell Ratio: Which Variable Determines Survival of Cervical Cancer Patients?” Clinical Cancer Research, Vol. 14, 2008, pp. 20-28.
[25]	V. Richards, “Cancer Immunology,” California Medicine, Vol. 112, No. 4, 1970, p. 52.